Common Side Effects and Their Frequencies
Nivolumab (Opdivo), a PD-1 inhibitor used for cancers like melanoma and lung cancer, causes side effects mainly from immune activation. In clinical trials, any-grade side effects occurred in 78-82% of patients, while grade 3-4 (severe) events hit 20-25%.[1][2]
Fatigue tops the list at 28-59% (all grades), with severe cases around 1-2%. Skin issues like rash or itching affect 20-40%, mostly mild. Gastrointestinal problems, including diarrhea (15-30%) and colitis (1-10%), are frequent but often manageable.[1]
Severe Immune-Related Adverse Events
Immune-mediated effects, unique to checkpoint inhibitors, arise in 20-40% of patients overall. Pneumonitis (lung inflammation) occurs in 2-5% (severe in <1-3%). Endocrine issues like hypothyroidism affect 8-13%, hyperthyroidism 4-10%. Hepatitis shows in 1-7%, with severe liver enzyme elevations in 1-4%.[2][3]
Infusion reactions happen in 5-10% during or shortly after dosing.[1]
Frequencies by Cancer Type and Combination Therapy
Rates vary by indication and regimen. In melanoma monotherapy, fatigue is 49%, rash 40%; severe events 21%.[1] With ipilimumab, all-grade effects jump to 96%, severe to 55%, due to heightened immune response.[2]
For non-small cell lung cancer, fatigue is 28%, cough 25%; severe 18%.[1] Renal issues like nephritis occur in 1-2% across trials.[3]
| Side Effect Category | All Grades (%) | Grade 3-4 (%) |
|----------------------|----------------|---------------|
| Fatigue | 28-59 | 1-2 |
| Rash/Pruritus | 20-40 | <1-5 |
| Diarrhea | 15-30 | 1-3 |
| Pneumonitis | 2-5 | <1-3 |
| Endocrine (thyroid) | 8-20 | <1 |
Data pooled from pivotal trials (e.g., CheckMate studies).[1][2]
How Long Do Side Effects Last and When Do They Appear?
Most emerge within 2-12 weeks of starting, but can appear anytime. Mild ones resolve in weeks with monitoring; severe immune effects may need steroids or treatment holds, lasting months.[3] Late-onset events occur in 5-10% beyond 6 months.[2]
Management and Patient Risks
Oncologists monitor with labs and imaging. Risks rise with combos (e.g., 40% severe with chemo) or prior autoimmune disease. Fatalities from immune effects are rare (0.3-1.2%).[1][3] Patients report fatigue and skin issues most in real-world data, aligning with trials.[4]
Sources:
[1]: Opdivo Prescribing Information (BMS)
[2]: CheckMate Trial Data (NEJM)
[3]: FDA Label Analysis
[4]: DrugPatentWatch.com - Nivolumab Side Effects